Abstract
Prior to the development of new cancer technologies, metastatic Renal Cell Carcinoma (mRCC) had a poor prognosis. Fortunately, advances in treatment are allowing a growing population of patients to live with advanced or mRCC. While quality of life has been an area of investigation in this population as treatments advance, relatively little is known about the specific survivorship needs experienced by these patients in the modern treatment era. Using the five survivorship domains defined by the National Cancer Institute, this narrative review explores the literature addressing the survivorship needs of patients living with mRCC. Significant physical, mental, emotional, social and financial effects of mRCC are herein discussed. By comparing literature from the pre-combination treatment period to the modern era, this narrative review of the published literature highlights the significant gaps in our survivorship knowledge for this unique and expanding population. Specifically, this review identifies gaps in understanding of symptom burden, psychological impact, financial effects, and the particular impact of immune-checkpoint inhibitor based combination therapies. Here, we highlight these areas for further research with the hope of finding strategies to alleviate the effects of mRCC and improve the quality of life of patients living with metastatic disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
